Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CELEBREX

« Back to Dashboard
Celebrex is a drug marketed by Gd Searle and is included in one NDA. It is available from twenty-six suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in CELEBREX is celecoxib. There are twenty-one drug master file entries for this compound. Twenty-six suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the celecoxib profile page.

Summary for Tradename: CELEBREX

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list209
2013 Sales:$2,237,658,000

Pharmacology for Tradename: CELEBREX

Clinical Trials for: CELEBREX

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998-004Dec 15, 2006RXNoRE44048*PED<disabled><disabled>
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998-003Aug 29, 2002RXYesRE44048*PED<disabled><disabled>
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998-001Dec 31, 1998RXNo5,760,068*PED<disabled>Y<disabled>
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998-003Aug 29, 2002RXYes5,760,068*PED<disabled>Y<disabled>
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998-004Dec 15, 2006RXNo5,760,068*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CELEBREX

Drugname Dosage Strength RLD Submissiondate
celecoxibCapsules50 mgCelebrex3/21/2008

Non-Orange Book Patents for Tradename: CELEBREX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,521,207 Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation<disabled in preview>
5,466,823 Substituted pyrazolyl benzenesulfonamides<disabled in preview>
6,156,781 Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation<disabled in preview>
6,413,960 Substituted pyrazolyl benzenesulfonamides for the treatment of asthma<disabled in preview>
5,753,688 Substituted pyrazolyl benzenesulfonamides for the treatment of gastrointestinal conditions<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc